Locally Destructive Metastatic Basal Cell Carcinoma
Practice Points
- Risk factors associated with metastatic spread of basal cell carcinoma (BCC) include larger tumor size, greater depth of invasion, long duration of disease, failure to respond to conventional treatment, and prior radiation treatment in the affected area.
- The median interval between onset of BCC and metastasis has been shown to be approximately 9 years.
- Vismodegib can be an effective oral therapy for patients with metastatic BCC, locally advanced BCC, recurrence following surgery, or those who are not candidates for surgery or radiation.
To the Editor:
A 60-year-old woman with a history of lymphoma presented to the emergency department for evaluation of intermittent diarrhea and vomiting of 2 weeks’ duration. On presentation, a rather large dressing covering the entire right half of the face was noted. Removal of the bandage revealed a necrotic, extensively destructive, right-sided facial lesion with a fully exposed ocular globe (Figure 1). The patient lived alone and was accompanied by a neighbor, who disclosed that the lesion had been neglected and enlarged over the last 15 years. Moreover, the neighbor reported that the patient had recently experienced several episodes of vertigo and frequent falls.
On admission to the hospital, dermatology was consulted and initial workup included computed tomography (CT) scan of the head and maxillofacial region, which showed a destructive process involving the right frontotemporal bone, maxillofacial region, sphenoid, and skull base with exposure of intracranial contents (Figure 2). An aggressive wound care regimen was instituted. Biopsy of the wound margin revealed nodular and focally infiltrative basal cell carcinoma (BCC) (Figure 3).
and focally infiltrative basal cell carcinoma (H&E, original magnifications×4 and ×10).